PRTG Key Statistics, Chart & Performance
The current stock price of PRTG is 6.81 USD. In the past month the price decreased by -2.99%. In the past year, price increased by 129.29%.
PRTG Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.34 | 406.46B | ||
| AMGN | AMGEN INC | 15.22 | 179.28B | ||
| GILD | GILEAD SCIENCES INC | 15.23 | 154.71B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.66 | 117.45B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.44 | 82.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 785.47 | 52.92B | ||
| INSM | INSMED INC | N/A | 37.94B | ||
| NTRA | NATERA INC | N/A | 32.26B | ||
| BIIB | BIOGEN INC | 10.58 | 25.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.22 | 21.84B | ||
| INCY | INCYTE CORP | 15.59 | 19.65B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Related stock screener links
About PRTG
Company Profile
Portage Biotech, Inc. is a biotechnology company, which engages in the research and development of immuno-oncology therapies for patients with cancer. The firm is engaged in advancing therapies to improve long-term treatment, response, and quality of life in patients with cancers. The Company’s access to technologies coupled with biological mechanisms enables the identification of clinical therapies and product development strategies, which accelerate these medicines through the translational pipeline. Its adenosine antagonist platform include PORT-9 and PORT-8. PORT-9 and PORT-8 are in the preclinical stage. Its PORT-8 is a dual inhibitor of adenosine receptors 2A and 2B (A2A/A2B) to address solid tumors. Its PORT-9 is an A2B antagonist designed to treat colorectal and gastrointestinal cancers. Its iNKT Engager platform includes PORT- 3, which is in Phase I.
Company Info
PORTAGE BIOTECH INC
Clarence Thomas Building, P.O. Box 4649, Road Town
Tortola ONTARIO VG1110 VG
CEO: Ian Walters
Employees: 4
Phone: 4167377600
PORTAGE BIOTECH INC / PRTG FAQ
Can you describe the business of PORTAGE BIOTECH INC?
Portage Biotech, Inc. is a biotechnology company, which engages in the research and development of immuno-oncology therapies for patients with cancer. The firm is engaged in advancing therapies to improve long-term treatment, response, and quality of life in patients with cancers. The Company’s access to technologies coupled with biological mechanisms enables the identification of clinical therapies and product development strategies, which accelerate these medicines through the translational pipeline. Its adenosine antagonist platform include PORT-9 and PORT-8. PORT-9 and PORT-8 are in the preclinical stage. Its PORT-8 is a dual inhibitor of adenosine receptors 2A and 2B (A2A/A2B) to address solid tumors. Its PORT-9 is an A2B antagonist designed to treat colorectal and gastrointestinal cancers. Its iNKT Engager platform includes PORT- 3, which is in Phase I.
Can you provide the latest stock price for PORTAGE BIOTECH INC?
The current stock price of PRTG is 6.81 USD. The price decreased by -2.16% in the last trading session.
Does PORTAGE BIOTECH INC pay dividends?
PRTG does not pay a dividend.
What is the ChartMill rating of PORTAGE BIOTECH INC stock?
PRTG has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What sector and industry does PORTAGE BIOTECH INC belong to?
PORTAGE BIOTECH INC (PRTG) operates in the Health Care sector and the Biotechnology industry.
PRTG Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to PRTG. When comparing the yearly performance of all stocks, PRTG is one of the better performing stocks in the market, outperforming 92.16% of all stocks.
PRTG Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to PRTG. Both the profitability and financial health of PRTG have multiple concerns.
PRTG Financial Highlights
Over the last trailing twelve months PRTG reported a non-GAAP Earnings per Share(EPS) of -5.72. The EPS increased by 92.66% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -304.13% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |